View Older Stories View More Recent Stories
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
AstraZeneca to move listing from NASDAQ to NYSE in January
-
Guggenheim Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
-
AstraZeneca acquires Modella AI to expand oncology AI capabilities
-
Walmart to join Nasdaq-100 Index effective January 20
-
AstraZeneca names Rick R. Suarez as US president and biopharmaceuticals head
-
AstraZeneca's Saphnelo shows positive results in lupus trial
-
BBVA USA (BBVA) and Haleon (HLN) Added to Goldman's European Conviction List Director's Cut for January 2026
-
ENHERTU receives breakthrough designation for early breast cancer treatment
-
AstraZeneca's (AZN) ENHERTU receives breakthrough therapy designation for early breast cancer
-
Trump to announce prescription drug price agreements
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
EMA validates application for DATROWAY as first-line treatment for TNBC
-
ENHERTU plus pertuzumab wins FDA approval for HER2-positive breast cancer
-
ENHERTU plus pertuzumab approved for first-line HER2+ metastatic breast cancer
-
AstraZeneca (AZN) PT Raised to $105 at TD Cowen
-
FDA launches fresh safety scrutiny of approved RSV therapies for infants - Reuters
-
AstraZeneca selects Salesforce Agentforce for global customer engagement
-
AstraZeneca presents largest-ever ASH presence with new blood cancer data
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP155 at Morgan Stanley
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
This pharma stock is BofA's Top Pick going into 2026
-
AstraZeneca wins FDA approval for IMFINZI as first perioperative immunotherapy for early gastric cancers
-
Bernstein on IRA pricing: $245 really is the floor
-
AstraZeneca's Imfinzi gets FDA approval for early gastric cancer treatment
-
AstraZeneca (AZN) PT Raised to $108.50 at BofA Securities
-
AstraZeneca announces $2 billion Maryland manufacturing expansion
-
AstraZeneca (AZN) PT Raised to $87 at Leerink Partners
-
baxdrostat shows significant blood pressure reduction in resistant hypertension trial
-
AstraZeneca's FASENRA shows positive results in rare blood disorder trial
-
Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca
-
AstraZeneca (AZN) Tops Q3 EPS by 122c; offers guidance
-
AstraZeneca earnings preview Q3: stronger print expected, focus on US prices, pipeline
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
AstraZeneca (AZN) call put ratio 2.1 calls to 1 put into quarter results
-
AstraZeneca's gefurulimab meets primary endpoint in myasthenia gravis trial
-
AstraZeneca's Alexion to present gefurulimab trial data at neurology meetings
-
Koselugo wins EU approval for adult neurofibromatosis type 1 tumors
-
Jefferies Upgrades AstraZeneca (AZN:LN) (AZN) to Buy
-
Tezspire wins EU approval for chronic rhinosinusitis with nasal polyps
-
AstraZeneca's Tezspire gets FDA approval for nasal polyp condition
-
UK closes in on drug pricing deal with White House - FT
-
AstraZeneca's IMFINZI shows 32% risk reduction in bladder cancer trial
-
AstraZeneca's IMFINZI shows survival benefit in early gastric cancer trial
-
AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk
-
Deutsche Bank Downgrades AstraZeneca (AZN:LN) (AZN) to Sell
-
AstraZeneca completes $445 million Texas facility expansion
-
AstraZeneca opens expanded Texas manufacturing facility
-
AstraZeneca presents initial data from four pivotal cancer trials at ESMO
